Download Mad1 Modified Polypeptides : Specific Inhibition of the Growth and

TECHNICAL FILE - MEDICAL TECHNOLOGIES AND LABORATORY RESEARCH TOOLS
Mad1 Modified Polypeptides : Specific Inhibition of the Growth and
Proliferation of Myc-Deregulated Tumor Cells
Background
The technology consists of modified versions of a natural polypeptide that specifically inhibits growth and proliferation of cancer
cells in which the Myc oncogene has a deregulated expression and/or function.
Description
- Enter spontaneously into cells and translocate to the nucleus;
- Sequester Max (Myc obligate heterodimerization partner);
- Compete for DNA binding to promoters and enhancers of oncogenic target genes (Figure 1);
- Induce apoptosis or senescence in tumor cells;
- Specificity for Myc-deregulated tumor cells (70 % of all cancer (Dang, 2012)).
Possible Applications
Tumors and tumor cells addicted to Myc deregulated and amplified transcriptional activities such as brain, colon and lung cancers
and others (70 % of all cancer (Dang, 2012)).
The gold-standard treatment consists in chemotherapy and radiotherapy (one-sized fits all model, high secondary effects).
High and persistent oncogenic levels Myc, lead to a metabolic, growth and proliferative reprogramming that establish a new
homeostasis in tumor cells (Wolf et al, 2014). Such tumor cells become addicted to Myc activities. As demonstrated by key genetic
experiments (Felscher et al (2002) Science & Soucek et al (2008) Nature), this addiction can be exploited as a therapeutic strategy.
Indeed, it was shown that even the transient inhibition of Myc allows rapid regression of tumors in transgenic mouse models
without causing serious side effects.
Business Advantages of this solution
- Mad1* polypeptides can be expressed in high amount and purified easily;
- Mad1* polypeptides are highly cell permeable,
- No need for liposomes or use of viral approach for gene transfer into cells;
- Specific apoptosis triggered in tumors cells addicted to Myc.
Intellectual Property Status
IP provisional for the Mad1* derived polypeptides and uses thereof filed
Main Inventor Contact
TECHNICAL FILE - MEDICAL TECHNOLOGIES AND LABORATORY RESEARCH TOOLS
Pr Pierre Lavigne
Département de biochimie
Ph. D. Biophysique (Université du Québec, CAN, 1994)
Postdoc. Biologie structurale (University of Alberta, CAN, 1999)
Professeur agrégé
Téléphone: 819 820-6868 poste: 15462 Téléphone: 819 820-6868 poste: 15811 Téléphone: 819 820-6868 poste: 15463 Télécopieur: 819 564-5400 Courriel: [email protected]
Page Web: http://pages.usherbrooke.ca/plavigne/plv.html
TransferTech Sherbrooke Contact